good morning america semaglutide For the first time, Medicare will cover GLP-1s for obesity-related weight loss, without any other medical conditions. Starting Wednesday, eligible Medicare beneficiaries can receive GLP-1s for obesity for $50 per month by New study suggest weight loss

GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)commonly affect bowel movements, though responses vary widely among patients

People taking these medicines may require dose adjustments to their existing treatments under medical supervision

Mounjaro, a dual GIP and GLP-1 receptor agonist, offers enhanced appetite and blood sugar control mechanisms

For others, very high protein does produce enough gluconeogenesis to reduce ketone production

10 Its suitable only for people who have titrated through the standard doses and tolerated 2.4 mg well, so its not a starting dose

Aminoglycosides, tetracyclines, and certain other antibiotics may alter gut microbiota composition, potentially affecting the small amount of vitamin B12 that is produced by colonic bacteria, though this is generally not clinically significant for patients receiving injectable B12 supplementation